Whereas hundreds of millions of Americans are currently living with disabling and debilitating brain disorders; Whereas an additional 1,200,000 people aged 18 years and older are diagnosed annually with adult onset brain disease or disorders in the United States; Whereas neurological conditions impact Americans of all ages, but the risk of neurodegenerative diseases increases dramatically with age; Whereas the number of older Americans is growing rapidly, and more people will be affected by neurodegenerative diseases in coming decades; Whereas brain disease has a tremendous impact on individuals, families, and society; Whereas there is a critical need to improve the understanding of what causes neurological diseases, including neurodegenerative, neurodevelopmental, and psychiatric disorders, to develop new approaches for prevention and treatment; Whereas, in 2022, 6,500,000 Americans were estimated to be living with Alzheimer’s disease; Whereas an estimated 1,200,000 people in the United States could be living with Parkinson’s disease by 2030; Whereas about 1 in 6 children in the United States has 1 or more developmental disabilities or other developmental delays; Whereas serious mental illness is rising, with over 58,000,000 Americans experiencing a mental illness in 2021; Whereas 46,300,000 people aged 12 or older in the United States reported having substance use disorder in 2021; Whereas the underlying causes of most neurological conditions remain largely unknown due to the vast complexity of the human brain; Whereas through research, the underlying causes of a greater number of neurological conditions can be understood; Whereas the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) support research on new ways to treat, cure, and prevent neurological conditions; Whereas the Director of the Center for Drug Evaluation and Research of the FDA testified before Congress in 2021 that the field of neuroscience requires more research to develop new, safe, and effective treatments